Nanjing Accelas Pharmaceutical

Nanjing Accelas Pharmaceutical is a clinical-stage biotechnology company headquartered in Nanjing, China, specializing in the development of targeted small molecule therapeutics for cancer and autoimmune conditions. The company's lead candidate, Avitinib (AC0010), is a third-generation EGFR inhibitor designed to treat T790M-mutation positive non-small cell lung cancer, which has undergone Phase 3 clinical trials. Accelas is also advancing AC0058, a selective Bruton's tyrosine kinase (BTK) inhibitor, for autoimmune indications such as systemic lupus erythematosus. By focusing on precision medicine, the company aims to provide more effective and safer treatment options for patients with refractory diseases. The company was founded by industry veterans with extensive experience in drug discovery and has established a robust pipeline of kinase inhibitors. Accelas maintains a strong focus on the Chinese market while seeking global development opportunities for its innovative portfolio.